Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
OBJECTIVE
We conducted a phase II trial in Japan to evaluate the efficacy and tolerability of weekly paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) as neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC).


METHODS
Patients with clinical stage IIIA-IIIB breast cancer received NAC consisting of 12 once-a-week cycles of paclitaxel followed by 4 once-every-third-week cycles of FEC.


RESULTS
Fifty patients with LABC were enrolled, 47 of whom were administered paclitaxel followed by FEC as NAC. The clinical response rate for all chemotherapies was 85.1%, and the pathological complete response rate was 27.7%. Regarding toxicity, grade 3-4 neutropenia was observed in 10% of patients. No serious toxicities requiring the discontinuation of treatment were encountered. The rate of breast conservation surgery was 31.9%, median survival had not been reached at the time of conclusion of this study, and the 3-year survival rate was 85.1%. Median disease-free survival was 40.2 months, and the 3-year disease-free survival rate was 62.1%.


CONCLUSIONS
Weekly paclitaxel followed by FEC demonstrated efficacy and tolerable toxicity in a neoadjuvant setting for LABC.
Taguchi
Tetsuya
T
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. ttaguchi1@me.com
Masuda
Norikazu
N
Nakayama
Takahiro
T
Motomura
Kazuyoshi
K
Tsukamoto
Fumine
F
Shimazu
Kenzo
K
Nomura
Takashi
T
Morimoto
Takashi
T
Yamamoto
Hiroshi
H
Wakita
Kazuyuki
K
Nakano
Yoshiaki
Y
Yoneda
Kohri
K
Inaji
Hideo
H
Takatsuka
Yuichi
Y
Noguchi
Shinzaburo
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use / Q000633:toxicity; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use* / Q000633:toxicity; D017698:Postmenopause; D017697:Premenopause; D016019:Survival Analysis
D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil